HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Litvan, I. Articles by Hutton, M. Search for Related Content PubMed PubMed Citation Articles by Litvan, I. Articles by Hutton, M. Related Collections All Movement Disorders

Tau genotype: No effect on onset, symptom severity, or survival in progressive supranuclear palsy

From the Cognitive Neuropharmacology Unit (Dr. Litvan), Henry Jackson Foundation; and the Birdsall Research Building (Dr. Hutton and M. Baker), Mayo Clinic Jacksonville, FL.

Address correspondence and reprint requests to Dr. Irene Litvan, Cognitive Neuropharmacology Unit, Henry M. Jackson Foundation, The Champlain Building, 6410 Rockledge Drive, Suite 600, Bethesda, MD 20817-1844; e-mail: ilitvan{at}dvhip.org

Genetic studies have shown that progressive supranuclear palsy (PSP) is associated with inheritance of a specific genotype (H1/H1) in the tau gene. The authors investigated whether the H1/H1 genotype or A0/A0 genotype independently or in conjunction with selected environmental risk factors influences the age at onset, severity, or survival in patients with PSP. Our findings suggest that tau genotyping does not predict the prognosis of PSP.

This article has been cited by other articles:

				K Tawana and D B Ramsden Progressive supranuclear palsy Mol. Pathol., December 1, 2001; 54(6): 427 - 434. [Abstract] [Full Text] [PDF]